Occurrence and determinants of trimethoprim/sulfamethoxazole use in pregnancy

References

• Sivojelezova A, Einarson A, Shuhaiber S, Koren G; Motherisk Team. Trimethoprim-sulfonamide combination therapy in early pregnancy. Can Fam Phys. 2003;49:1085–6.
   PubMed Web of Science ®Google Scholar
• Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother. 2000; 46: 49–52
   Web of Science ®Google Scholar
• Huang E, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med. 2002; 162: 41–7
   PubMedGoogle Scholar
• Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can. 2004; 26: 475–80
   PubMedGoogle Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000; 343: 1608–14
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001; 153: 961–68
   PubMed Web of Science ®Google Scholar
• Czeisel A, Rockenbaer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population-based case control study. Reprod Toxicol. 2001; 15: 637–46
   PubMed Web of Science ®Google Scholar
• Meijer WM, Walle HEK, Kerstjens-Frederikse WS, Jong-van den Berg LTW. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol. 2005; 20: 203–7
   PubMed Web of Science ®Google Scholar
• Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J. Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf. 2006; 15: 327–37
   PubMed Web of Science ®Google Scholar
• Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004; 191: 398–407
   PubMed Web of Science ®Google Scholar
• Riley EH, Fuentes-Afflick E, Jackson RA, Escobar GJ, Brawarsky P, Schreiber M, et al. Correlates of prescription drug use during pregnancy. J Womens. Health. 2005; 14: 401–9
   Web of Science ®Google Scholar
• Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol. 1987; 157: 148–56
   PubMed Web of Science ®Google Scholar
• Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol. 1991; 165: 33–40
   PubMed Web of Science ®Google Scholar
• Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol. 1993; 46: 581–9
   PubMed Web of Science ®Google Scholar
• Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006; 113: 559–68
   PubMed Web of Science ®Google Scholar
• Garriguet D. Medication use among pregnant women. Health Rep. 2006; 17: 9–18
   PubMedGoogle Scholar
• Lee E, Maneno MK, Smith L, Weiss SR, Zuckerman IH, Wutoh AK, et al. National patterns of medication use during pregnancy. Pharmcoepidemiol Drug Saf. 2006; 15: 537–45
   PubMed Web of Science ®Google Scholar
• Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006; 194: 961–6
   PubMed Web of Science ®Google Scholar
• Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992; 45: 197–203
   PubMed Web of Science ®Google Scholar
• Masters PA, O'Bryan TA, Zurlo J, Miller D, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003; 163: 402–10
   PubMed Web of Science ®Google Scholar
• Banhidy F, Acs N, Puho EH, Czeizel AE. Maternal urinary tract infection and related drug treatments during pregnancy and risk of congenital abnormalities in the offspring. BJOG. 2006; 113: 1465–71
   PubMed Web of Science ®Google Scholar
• Jolly MC, Sebire N, Harris J, Robinson S, Regan L. Obstetric risks of pregnancy in women less than 18 years old. Obstet Gynecol. 2000; 96: 962–6
   PubMed Web of Science ®Google Scholar
• Al-Haddad AM. Urinary tract infection among pregnant women in Al-Mukalla district, Yemen. East Med Health J. 2005; 11: 505–10
   PubMedGoogle Scholar
• Rothman KJ. Modern epidemiology, second edition. Little, Brown and Company, Boston, MA 1998
   Google Scholar
• Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during pregnancy: its association with maternal morbidity and perinatal outcome. Am J Public Health. 1994; 84: 405–10
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S. Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiol Drug Saf. 2006; 15: 613–7
   PubMed Web of Science ®Google Scholar
• Williams JI, Young W. A summary of the quality of health care administrative databases in Canada. Patterns of health care in Ontario. The ICES practice atlas, second edition, V Goel, JI Williams, GM Anderson, P Blackstien-Hirsch, C Fooks, CD Naylor. Canadian Medical Association, Ottawa 1996
   Google Scholar